Biotech Values

[p3analyze]

>> Even if GPNMB testing/selection was biased,<<

CMO stated more than 90% patients screened ended up being enrolled - implying the threshold that at least 5% cells need to be stained positive for GPNMB was too low, and not selective enough.

Therefore what's the reason for triple negative tumors to appear to respond better to a GPNMB adc? Do they naturally express more GPNMB than the HER2 or ER/PR positive tumors?